Sintilimab Triplet Demonstrates Efficacy With Acceptable Safety in pMMR/MSS CRC
The triplet combination of sintilimab, chidamide, and bevacizumab resulted in a high 18-week progression-free survival rate with a favorable toxicity profile in patients with microsatellite stable or mismatch repair–proficient metastatic colorectal cancer, according to data from the phase 2 CAPability-01 trial.
Source: onclive.com